<DOC>
	<DOCNO>NCT01016340</DOCNO>
	<brief_summary>This phase II randomize , double-blind , placebo-controlled study eligible subfertile male subject ( age 20 year ) .</brief_summary>
	<brief_title>Efficacy Safety MCS-5 Treating Male Oligoasthenospermia</brief_title>
	<detailed_description />
	<criteria>1 . Male subject 20 year old old 2 . Subjects diagnose idiopathic oligoasthenospermia 3 . Subjects normal baseline hormone profile 4 . Subjects able impregnate female partner past 12 month active unprotected sexual life 5 . Subject 's female partner endocrine genital obstructive disorder capable impregnation . 6 . Subjects acceptable baseline liver function 7 . Subjects normal baseline renal function . 1 . Subjects diagnose male infertility 5 year . 2 . Subjects baseline semen white blood cell count 1*106/mL . 3 . Subjects genital/seminal tract obstruction , infection , inflammation anatomic abnormality . 4 . Subjects whose female partner diagnose infertility kind . 5 . Male infertility associate hormonal deficiency/imbalance , poor nutrition , congenital/chromosomal disorder , erectile dysfunction , psychological disorder . 6 . Subjects plan undergo artificial insemination kind within study period . 7 . Subjects treat chemotherapy , pelvic irradiation major pelvic surgery 8 . Subjects undergo invasive procedure within study period 9 . Subjects undergo chemotherapy radiotherapy kind study period . 10 . Subjects willing undergo twoweek washout period reason .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Male Oligoasthenospermia</keyword>
	<keyword>MCS</keyword>
</DOC>